Mer is found to be aberrantly expressed in non-small cell lung cancer and other malignancies, and the presence of Mer has been implicated in resistance to therapy with tyrosine kinase inhibitors [34]. This evidence concerns the gene MERTK and non-small cell lung carcinoma.